Item 5.07 Submission of Matters to a Vote of Security Holders.


The 2022 annual meeting of stockholders of Enzon Pharmaceuticals, Inc. (the
"Company") was held on June 9, 2022. At the 2022 annual meeting of stockholders,
the Company's stockholders voted on the following matters as described in the
Company's proxy materials: (1) the election of three directors, each for a
one-year term expiring at the Company's next annual meeting of stockholders and
until such director's successor is elected and qualified, (2) the ratification
of the appointment of EisnerAmper LLP as the Company's independent registered
public accounting firm for the fiscal year ending December 31, 2022, and (3) the
approval, on an advisory basis, of the compensation of the Company's named
executive officers. A total of 55,134,730 shares of common stock were present or
represented by proxy at the 2022 annual meeting of stockholders, representing
approximately 74% of the total shares of common stock entitled to vote at the
2022 annual meeting of stockholders.

1. Election of Directors - The Company's stockholders elected each of the


    following individuals as a director for a one-year term expiring at the
    Company's next annual meeting of stockholders and until such director's
    successor is elected and qualified, as set forth below:




Nominee                                  Votes For        Votes Against       Abstentions       Broker Non-Votes
Jordan Bleznick                           44,395,016             539,439           106,468             10,093,807

Jaffery (Jay) A. Firestone                44,425,550             510,176   

       105,197             10,093,807
Randolph C. Read                          44,377,601             556,825           106,497             10,093,807

2. Ratification of the appointment of EisnerAmper LLP as the Company's

independent registered public accounting firm for the fiscal year ending

December 31, 2022 - This proposal was approved as set forth below:




Votes For       Votes Against       Abstentions
54,499,934             514,806           119,990

3. Approval, on an advisory basis, of the compensation of the Company's named


    executive officers - This proposal was approved as set forth below:




Votes For       Votes Against      Abstentions       Broker Non-Votes
40,115,897           2,941,985        1,983,041             10,093,807

© Edgar Online, source Glimpses